GSE1710

Expression profiling in inflammatory bowel disease

Whole-study status Not suitable

Dataset does not meet the current suitability threshold.

Whole-study downloads — these do not apply your sample requirements.

Selected cohort requirements

Samples meeting selected requirements: 0 cases / 0 controls

View matching samples

10 case / 11 control samples elsewhere in the study have incomplete or conflicting evidence; they are not included above

Patient pairs verified in indexed sample metadata: 0

A case/control comparison meeting these requirements is not confirmed.

Counts describe samples, not independent patients. Pair verification uses explicit subject identifiers in indexed sample metadata. Zero verified pairs does not establish that the study is unpaired; reported matched-normal design alone is insufficient.

Summary

The series was designed to identify new genes involved in the pathophysiology of inflammatory bowel disease (Crohn's disease and ulcerative colitis). This series represents a group of 31 samples, subdivided into 3 groups: 1) Normal controls: 11 samples; 2) patients with Crohn's diseases: 10 samples; 3) patients with ulcerative colitis: 10 samples. Each sample originated from a different patient or normal control, in total n=31 individuals were examined. Keywords = Inflammatory bowel disease Keywords = Crohn's disease Keywords = ulcerative colitis Keywords = expression screening Keywords = expression profiling Keywords: other

Overall design

Source Evidence

4 sources
Source Contribution Status
GEO

Original dataset metadata, sample metadata, source links, and GEO data availability flags.

Sample records
31 GSM samples
Primary source
recount3

Planned trusted source for processed count availability.

No match found
Expression Atlas

Planned source for curated expression experiment links.

No match found
PubMed

Primary GEO citations and related PubMed articles that mention this dataset.

1 linked publication 1 DOI

Primary publication

  1. Dissection of the inflammatory bowel disease transcriptome using genome-wide cDNA microarrays. PLoS medicine, 2005
Available

Metadata Quality Components

Analysis Readiness

Review before analysis
85% DE readiness

Contrast completeness

25/25 pts

Both case and control groups are present in the proposed grouping.

Minimum group size

20/20 pts

Each contrast group has at least 2 samples.

Processed data availability

20/20 pts

Processed data is marked available in the GEO index.

Sample decision clarity

3/15 pts

Unassigned or review-needed samples remain before analysis.

Blocking warnings

7/10 pts

Warnings are present, but none are critical blockers.

Metadata normalization

10/10 pts

Metadata quality is high enough to support downstream handoff.

Blockers

  • 10 samples are still unassigned.

Next Steps

  • Resolve unassigned or review-needed samples in the grouping table.

Analysis Preparation Checklist

4/6 ready

Group labels reviewed

Needs review

Siftome proposed case and control labels, but no reviewer confirmation is stored yet.

Open the sample grouping CSV and confirm group labels before analysis.

Minimum sample count met

Ready

Both groups meet the minimum of 2 samples.

Confirm whether the cohort is large enough for the intended statistical analysis.

Processed counts available

Ready

Processed data availability is marked true in the GEO index.

Verify that downloaded processed files contain usable count or expression identifiers.

Ambiguous samples handled

Needs review

0 review-needed samples and 10 unassigned samples remain.

Resolve ambiguous and unassigned samples before finalizing the contrast.

Exclusion decisions recorded

Ready

No hard-excluded samples were detected by the current rules.

Record any manual exclusions in the downstream analysis notes.

Source traceability preserved

Ready

The dataset and sample accessions can be traced back to GEO.

Keep GEO accessions with exported metadata.

Bioinformatician Review

Bioinformatician review required

Ask a bioinformatician to review grouping, count availability, exclusions, and design before DE.

Analysis readiness has blockers that must be resolved before DE.

One or more samples are unassigned and need manual grouping decisions.

Assay context may require expert handling before DESeq2-style analysis.

Why This Is Ranked Here

Tumor vs normal
Not suitable Dataset does not meet the current suitability threshold.

Applied Review Decisions

No active review decisions affect this ranking.

Derived Classifications

  • Assay differs from search intent Microarray Search intent expects bulk RNA-seq. Assay came from Normalization rules.
  • Disease context Crohn's disease, inflammatory bowel disease, ulcerative colitis Disease context came from Normalization rules.
  • Likely case group Crohn's disease 10 samples
  • Likely control group Control 11 samples

Intent Interpretation

  • Downgrade or exclusion reason Downgraded assay: microarray cohorts are separated from the RNA-seq intent. Derived from current-intent ranking reasons.

Ranking Facts

Supporting evidence

  • Comparison: Disease/model vs control. Specimen: Biopsy. Comparison suitability: 0%.
  • Interpreted disease metadata: Crohn's disease, Inflammatory bowel disease, Ulcerative colitis.
  • Processed data is available for downstream review.
  • External evidence: PubMed links 1 publication; 1 DOI available: PMID 16107186.
  • Publication context: Dissection of the inflammatory bowel disease transcriptome using genome-wide cDNA microarrays.. PLoS medicine, 2005. PMID 16107186. DOI 10.1371/journal.pmed.0020199.

Cautions

  • Downgraded assay: microarray cohorts are separated from the RNA-seq intent.
  • Disease/control design without a tumor/normal comparison is outside tumor/normal triage.
  • Overall score capped because comparison suitability is weak for the selected search intent.
  • Comparison suitability score is below the Phase 1 recommended threshold.

Dataset Warnings

Normalized Fields

139 fields

Sample Group Preview

31 rows shown
Show Hide
Study totals: Case 10 | Control 11 | Unassigned 10 | Excluded 0 | Ambiguous 0 31 rows shown
Group Role Accession Title Source / characteristics Reason
Crohn's disease Case GSM29606 Crohn 01, CD01 Sigmoid colon biopsy None Case marker detected.
Crohn's disease Case GSM29607 Crohn 02, CD02 Sigmoid colon biopsy None Case marker detected.
Crohn's disease Case GSM29608 Crohn 03, CD03 Sigmoid colon biopsy None Case marker detected.
Crohn's disease Case GSM29609 Crohn 04, CD04 Sigmoid colon biopsy None Case marker detected.
Crohn's disease Case GSM29610 Crohn 05, CD05 Sigmoid colon biopsy None Case marker detected.
Crohn's disease Case GSM29611 Crohn 06, CD06 Sigmoid colon biopsy None Case marker detected.
Crohn's disease Case GSM29612 Crohn 07, CD07 Sigmoid colon biopsy None Case marker detected.
Crohn's disease Case GSM29613 Crohn 08, CD08 Sigmoid colon biopsy None Case marker detected.
Crohn's disease Case GSM29614 Crohn 09, CD09 Sigmoid colon biopsy None Case marker detected.
Crohn's disease Case GSM29615 Crohn 10, CD10 Sigmoid colon biopsy None Case marker detected.
Control Control GSM29595 Control 01, NC01 Sigmoid colon biopsy None Sample-local control marker detected.
Control Control GSM29596 Control 02, NC02 Sigmoid colon biopsy None Sample-local control marker detected.
Control Control GSM29597 Control 03, NC03 Sigmoid colon biopsy None Sample-local control marker detected.
Control Control GSM29598 Control 04, NC04 Sigmoid colon biopsy None Sample-local control marker detected.
Control Control GSM29599 Control 05, NC05 Sigmoid colon biopsy None Sample-local control marker detected.
Control Control GSM29600 Control 06, NC06 Sigmoid colon biopsy None Sample-local control marker detected.
Control Control GSM29601 Control 07, NC07 Sigmoid colon biopsy None Sample-local control marker detected.
Control Control GSM29602 Control 08, NC08 Sigmoid colon biopsy None Sample-local control marker detected.
Control Control GSM29603 Control 09, NC09 Sigmoid colon biopsy None Sample-local control marker detected.
Control Control GSM29604 Control 10, NC10 Sigmoid colon biopsy None Sample-local control marker detected.
Control Control GSM29605 Control 11, NC11 Sigmoid colon biopsy None Sample-local control marker detected.
Unassigned Unassigned GSM29616 Colitis 01, UC01 Sigmoid colon biopsy None No explicit case or control marker detected.
Unassigned Unassigned GSM29617 Colitis 02, UC02 Sigmoid colon biopsy None No explicit case or control marker detected.
Unassigned Unassigned GSM29618 Colitis 03, UC03 Sigmoid colon biopsy None No explicit case or control marker detected.
Unassigned Unassigned GSM29619 Colitis 04, UC04 Sigmoid colon biopsy None No explicit case or control marker detected.
Unassigned Unassigned GSM29620 Colitis 05, UC05 Sigmoid colon biopsy None No explicit case or control marker detected.
Unassigned Unassigned GSM29621 Colitis 06, UC06 Sigmoid colon biopsy None No explicit case or control marker detected.
Unassigned Unassigned GSM29622 Colitis 07, UC07 Sigmoid colon biopsy None No explicit case or control marker detected.
Unassigned Unassigned GSM29623 Colitis 08, UC08 Sigmoid colon biopsy None No explicit case or control marker detected.
Unassigned Unassigned GSM29624 Colitis 09, UC09 Sigmoid colon biopsy None No explicit case or control marker detected.
Unassigned Unassigned GSM29625 Colitis 10, UC10 Sigmoid colon biopsy None No explicit case or control marker detected.

Use as Discovery Cohort

External Validation Finder

Carry Siftome's disease, organism, specimen, assay, data type, and accession into a validation project. Uncertain fields remain Unknown.